Join the SOSV DEEP TECH SUMMIT, NOV 4-6. (FREE AND VIRTUAL ) Register Today →

Inixi Bio

Stopping cancer at stage zero

Company details

Inixi Bio is building tumor initiation inhibitors for patients with high cancer risk—like statins for cancer

Most cancer drugs chase tumors after they appear. Inixi Bio is daring to build the opposite: a once-monthly preventive designed to interrupt tumor initiation, the moment cancer begins, so patients never have to play catch-up. Prevention has already transformed other killers (think vaccines and the “statin moment” in heart disease). We believe oncology is next.

Founder Jon Spalding turned down a faculty position at Washington University at St. Louis to pursue his life’s work at Inixi Bio – to build the first cancer prevention drug. His groundbreaking insight into an oddity of genetics – a rare population of humans who never get cancer – led to a discovery of a key, conserved target that can shut down cancer right at its inception.

Cancer is responsible for 30% of deaths. Could changing that number make this actually a longevity drug? Maybe. Inixi is taking a smart clinical path. Within the next 3 years, Inixi will start trials where the need and the signal are unambiguous, an inherited cancer syndrome with near-certain early malignancy by age 30. These patients face aggressive surveillance, disfiguring surgeries, or worse by young adulthood. Swift trials with small numbers of patients provide a clear path to accelerated approval for their lead drug candidate, after which they can set their sights on proving the long but lucrative premise of stopping cancer before it happens – population wide.

Inixi is shifting cancer from late rescue to early prevention, measurably reducing procedures, surgeries, and fear. If we’re right, this isn’t just another oncology drug; it’s a new category: proactive cancer risk reduction at population scale.

Clear path to clinical trials within 3 years

Inixi Bio Quote Image
Dr. Jon Spalding, CEO and Co-Founder
“We’ve identified the specific genetic 'off-switch' used by the world's most cancer-resistant people.”

Team

Jonathan Spalding

CEO & Co-Founder

Keaton Carano

CFO & Co-Founder

Get In Touch with Inixi Bio

Please tell us a little bit about yourself and why you'd like to get connected. Inixi Bio + SOSV will follow up with you via email.

This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.